Present status of HMG reductase inhibitors in treatment of dyslipidemia.
HMG reductase inhibitors have significant desirable effects on patients with dyslipidemia. Multiple factors are involved in these desirable effects. Other factors that might play a role in the risk of coronary artery disease are fibrinogen concentration, homocysteine, Lp (a), small dense LDL, insulin resistance, and infection with chlamydia. High-dose reductase inhibitors may be indicated in select patients. The ideal end point may be 150 mg/dL for adults.
Kalmansohn
R B
RB
Department of Medicine, UCLA Medical Center, Los Angeles, California, USA.
Kalmansohn
R W
RW
Schiff
D L
DL
D000328:Adult; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors